Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy

Size: px
Start display at page:

Download "Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy"

Transcription

1 European Heart Journal (2002) 23, doi: /euhj , available online at on Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy A comparison of clinical, haemodynamic and exercise outcomes S. Firoozi, P. M. Elliott, S. Sharma, A. Murday, S. J. Brecker, M. S. Hamid, B. Sachdev, R. Thaman and W. J. McKenna Department of Cardiological Sciences, St George s Hospital Medical School, London, U.K. Aims Surgical myectomy has been successfully used to treat patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). More recently, alcohol septal ablation has been advocated as a less invasive, but equally effective alternative therapy. The aim of this nonrandomized cohort study was to compare subjective and objective outcomes in patients undergoing these therapies. Methods Forty-four patients (25 male; age years) with symptomatic drug-refractory obstructive HCM were studied. Twenty-four patients underwent surgical myectomy and 20 alcohol septal ablation. All patients underwent clinical evaluation, echocardiography and upright maximal cardiopulmonary exercise testing using a cycle ergometer before and following their intervention. Results Peak gradient was reduced to a similar extent by both modalities (myectomy: to mmhg (P< ); ablation: to mmhg (P< ); P=0 48 for myectomy vs ablation) and led to similar improvements in NYHA class (myectomy: to (P< ); ablation: to (P<0 0001);P=0 3 for myectomy vs ablation). Myectomy resulted in a greater improvement in peak oxygen consumption (myectomy: to ml. kg 1 min 1 (P< ); ablation: to ml. kg 1 min 1 (P<0 05); P<0 05 for myectomy vs ablation) and work rate achieved (myectomy: to watts (P<0 04); ablation: to watts (P=0 11); P<0 05 for myectomy vs ablation). Conclusion Surgical myectomy and alcohol septal ablation are equally effective at reducing obstruction and subjective exercise limitation in appropriately selected patients. However, the superior effect of surgical myectomy on exercise test parameters suggests that surgery remains the gold standard against which new treatment modalities should be compared. (Eur Heart J, 2002; 23: , doi: /euhj ) 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved. Key Words: Hypertrophic cardiomyopathy, obstruction, myectomy, alcohol septal ablation, peak oxygen consumption. Introduction Approximately 25% of patients with hypertrophic cardiomyopathy (HCM) have left ventricular outflow tract obstruction caused by contact between the anterior mitral valve leaflet and the interventricular septum Revision submitted 29 April 2002, and accepted 1 May Correspondence: Dr P. M. Elliott, Department of Cardiological Sciences, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, U.K. during systole [1,2]. When severe, left ventricular outflow tract obstruction can cause dyspnoea, chest pain, and syncope, and predisposes to the development of atrial arrhythmias [3]. For over four decades, surgical septal myotomy myectomy has been successfully used to treat drug-refractory patients with severe outflow tract obstruction [4 10]. More recently, transcoronary alcohol septal ablation has been proposed as a safer, less invasive alternative to surgery [11]. Two recently published studies comparing surgical myectomy and alcohol septal ablation have reported similar improvements in symptoms [12,13]. However, the X/02/$ The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

2 1618 S. Firoozi et al. Table 1 Baseline characteristics of the study subjects Myectomy group (n=24) Septal ablation group (n=20) P-value Age (years) Male sex 54% 60% 0 39 Drugs (%) β-blockers 8 (33) 9 (45) 0 43 CCA 4 (17) 6 (30) 0 29 Disopyramide 6 (25) 6 (30) 0 71 Amiodarone 4 (17) 3 (15) 0 88 Permanent AF Paroxysmal AF NYHA (%) Class II 15 (63) 14 (70) 0 61 Class III 8 (33) 6 (30) 0 81 Class IV 1 (4) Exertional chest pain (%) 12 (50) 9 (45) 0 74 Syncope (%) 5 (21) 2 (10) 0 33 MLVWT (mm) LA (mm) LVEDD (mm) LVESD (mm) FS (%) LVOTG (mmhg) Work (watts) Peak VO 2 (ml.kg 1 min 1 ) % Predicted peak VO AF=atrial fibrillation, CCA=calcium channel antagonist, FS=fractional shortening, LA=left atrium, LVEDD=left ventricular end-diastolic diameter, LVOTG=left ventricular outflow tract gradient, MLVWT=maximal left ventricular wall thickness, NYHA=New York Heart Association, VO 2 =oxygen consumption rate. comparative effects of alcohol ablation and surgery on exercise capacity remain uncertain because of a lack of standardized exercise protocols and the use of estimated rather than directly measured oxygen consumption [12]. The aim of this non-randomized single-centre cohort study was to make a direct comparison of subjective and objective clinical outcomes in patients undergoing these two treatment modalities. Methods Patients The study cohort comprised 44 patients (25 male; age years, range 14 to 74) with obstructive hypertrophic cardiomyopathy referred to the cardiomyopathy clinic at St George s Hospital Medical School, London, U.K., between 1990 and All patients had unexplained myocardial hypertrophy with a maximum left ventricular wall thickness exceeding two standard deviations from the normal range. All patients had drug refractory symptoms and a resting outflow tract gradient of at least 50 mmhg on continuous wave Doppler echocardiography (Table 1) and reported functional limitation (New York Heart Association class II or more) despite optimal medical therapy. The decision to proceed with septal myotomy myectomy or alcohol septal ablation was based on individual patient choice and physician guidance after extensive discussion of the benefits and risks of each therapeutic modality. Younger patients were encouraged to undergo surgery due to the paucity of long-term outcome data with alcohol septal ablation. Twenty-four patients ((13 male, 11 female) mean age years, range 14 to 74) underwent transaortic septal myotomy myectomy between April 1990 and September Twenty patients ((12 male, eight female), mean age years, range 25 to 62) underwent transcoronary alcohol septal ablation between May 1997 and May Echocardiography All patients underwent two-dimensional, M-mode, and Doppler echocardiography prior to their intervention and at regular follow-up clinics at St. George s Hospital using an Acuson 128 XP/10 (Mountain View, CA, U.S.A.), GE Vingmed system V (GE Ultrasound Europe, Horten, Norway) or a Hewlett-Packard Sonos 1000 (Hewlett-Packard, Andover, MA, U.S.A.). Standard views for M-mode and two-dimensional studies were obtained, and conventional techniques were used for sizing of the left atrium and ventricle. End-diastolic left ventricular wall thickness was recorded at the level of the mitral valve and papillary muscle in the anterior and posterior septum, and the lateral and posterior wall

3 Septal myotomy 1619 using short-axis two-dimensional images. Anterior and posterior septal thickness at the apex was assessed from the apical four-chamber and parasternal short-axis views. The maximum left ventricular wall thickness was defined as the maximal measurement recorded in any of the myocardial segments studied. Left ventricular outflow tract velocities were determined using continuous wave Doppler echocardiography, and left ventricular outflow tract gradients were calculated using the modified Bernoulli equation. Metabolic exercise testing Cycle ergometry exercise was performed (Sensormedics ergometrics 800S; Bitz, Germany) using a ramp protocol of 10 to 15 watts per min before and at each clinic visit after surgery or septal alcohol ablation. The ramp protocol was adjusted by assessing the subjective assessment of the patient s functional capacity to ensure appropriate test duration and to avoid premature fatigue. All patients were required to have a respiratory quotient (RQ) 0 85 prior to commencing exercise. Patients cycled at a rate of 60 to 70 revolutions per minute to the point of exhaustion or symptom limitation. Breath-by-breath gas exchange analysis was performed using a Sensormedics metabolic cart (V Max 29 Console, Sensormedics). Respiratory gases were sampled continuously via a mouthpiece and analysed with an 1111D/000 paramagnetic transducer for oxygen and a 2900 MMC non-dispersive infrared sensor for carbon dioxide. Peak oxygen consumption (peak VO 2 ) was defined as the highest VO 2 achieved during exercise. Results were expressed as percentage of the predicted maximal VO 2 to allow for age, gender and body size. A value of <80% of the predicted was considered abnormal. Septal myotomy myectomy Standard cardiopulmonary bypass and myocardial preservation techniques were used. Transoesophageal echocardiography was performed prior to bypass to determine the extent of myectomy required and to evaluate mitral valve morphology. The outflow tract was approached by way of an aortotomy, and the septal resection was initiated by making two parallel longitudinal incisions: the first beneath the nadir of the right coronary cusp and the second beneath the commisure separating the right and left coronary cusps. The incisions were joined superiorly and a mass of muscle was excised to the level of the papillary muscles. The resection was assessed prior to closure of the aortotomy using transoesophageal echocardiography. Transcoronary alcohol septal ablation A transvenous pacemaker lead was introduced via the femoral vein into the right ventricular apex and IU IV heparin was administered. Diagnostic coronary angiography was performed using standard techniques. The major proximal septal perforator was selected as the target vessel and selectively intubated with a inch guide wire introduced through an 8 F percutaneous transluminal coronary angioplasty guiding catheter. A short 2 mm over-the-wire balloon (15 mm length) was introduced and inflated. The distal vessel bed was opacified with angiographic contrast medium (Urograffin; Schering AG, Berlin, Germany) to ensure no dye reflux into the left anterior descending coronary artery (LAD) prior to alcohol injection. After verification of the correct balloon position, 0 5 to 1 ml of the echo contrast agent (Optison; Mallinckrodt Medical GmbH, Sieg, Germany) was injected through the inflated balloon catheter under continuous transthoracic echocardiographic imaging. Alcohol was given only when the area of maximum flow acceleration, that is, gradient formation, and opacified septal myocardium were adjacent to each other. Up to 5 ml of absolute alcohol (median 3 ml) was infused at 1 ml. min 1. The balloon remained inflated for 10 min after the alcohol administration to enhance tissue contact and to avoid alcohol reflux into the LAD. After deflation of the balloon, angiography was repeated to confirm successful blockage of the septal artery. Clinical follow-up All patients returned to the cardiomyopathy clinic at regular intervals following their procedure for a clinical evaluation, echocardiography and metabolic exercise testing. Statistics Data are expressed as mean SD. Paired t-tests were used to evaluate changes in continuous variables following LVOT gradient reduction in each group and unpaired t-tests were used for the comparison between the groups. For non-continuous variables the chi-square test was employed. Significance was set at a P-value <0 05. The software used for analysis was Statistica version 5.0 by Statsoft (Tulsa, Oklahoma, U.S.A.). Results Baseline assessment Patients in the septal ablation group were older than the surgical group, but were matched for other clinical characteristics, cardiac dimensions, baseline left ventricular outflow tract gradient and exercise parameters (Table 1). The baseline symptom status of the patients in the two groups is also summarized in Table 1. Post-therapy follow-up assessment The mean length of follow-up in the myectomy group was months and months in the

4 1620 S. Firoozi et al. Table 2 Cardiac dimensions following LVOTO reduction. (All measurements in mm except FS) Myectomy group Septal ablation group Before After P-value Before After P-value Maximal IVS thickness LVEDD LVESD LA FS (%) LVOTO=left ventricular outflow tract obstruction; IVS=interventricular septum; LVEDD=left ventricular end-diastolic diameter; LVESD=left ventricular end-systolic diameter; LA=left atrium; FS=fractional shortening. Table 3 Wall thickness change after LVOTO reduction. (All measurements in mm) Myectomy group Septal ablation group Before After P-value Before After P-value Mitral valve level Anterior septum < Posterior septum < Posterior wall Lateral wall Papillary muscle level Anterior septum < <0 01 Posterior septum Posterior wall Lateral wall Apical level Anterior wall < Posterior wall septal ablation group (P=0 02). There was one death in each group with one postoperative surgical death due to heart failure and one sudden death 21 days following septal ablation. Permanent dual chamber pacing was required in one patient (4%) in the surgical group and in three (15%) of the patients in the septal ablation group. Gradient By the end of follow-up, peak left ventricular outflow gradient fell from mmhg to mmhg in the myectomy group (P< ) and from mmhg to mmhg (P= ) in the septal ablation group (P=0 48 for the comparison between the groups). Twenty-one (91%) of the myectomy group had post-treatment gradients below 20 mmhg compared with 14 (74%) of the septal ablation group (P=0 09). Cardiac dimensions The changes in cardiac dimensions in the two groups are summarized in Table 2. In both groups, maximum interventricular septal thickness was reduced to the same extent. In the myectomy group, there was no significant change in left ventricular end-diastolic diameter or left ventricular end-systolic diameter and no change in left atrial size. There was a small decrease in systolic left ventricular fractional shortening. In the septal ablation group, there was no change in left ventricular end-diastolic diameter or left atrial size. There was an increase in left ventricular end-systolic diameter with a decrease in fractional shortening. Changes in individual myocardial wall segments are shown in Table 3. The extent of the change was more widespread in the myectomy group with significant reduction of wall thickness in the anterior and posterior septum at the mitral valve level, papillary muscle level and the apex. In contrast, the septal ablation group had more localized reductions in basal myocardial segments (Table 3). Symptoms Following surgical myectomy, NYHA functional class improved from to (P< ). Following septal ablation the NYHA functional class improved from to (P<0 0001). The improvement in functional class after therapy was similar in the two groups (P=0 3). At follow-up, 13 of the 23 patients in the myectomy group were in class I, eight were in class II and two were

5 Septal myotomy 1621 Figure 1 (a) NYHA class change following surgical myectomy. This figure shows the change in NYHA class distribution following myectomy. (b) NYHA class change following alcohol septal ablation. This figure shows the change in NYHA class distribution following alcohol septal ablation. in class III. Five patients reported no improvement in functional class (Fig. 1(a)), however four of the five patients reported an improvement in angina. In the septal ablation group, 10 of the 19 patients were in class I, seven were in class II and two were in class III. Seven patients reported no improvement in functional class (Fig. 1(b)), however four of the seven experienced an improvement in angina. Overall, the number of patients reporting angina decreased from 12 to six in the myectomy group and from nine to four in the septal ablation group (P=0 19 for comparison of the groups). Two patients in the myectomy group and one in the septal ablation group experienced syncope during follow-up. Exercise testing All patients reached a peak exercise RQ >1, with a rise of at least 0 15 and a plateau in the oxygen consumption curve. There was no difference before or after treatment with respect to peak exercise RQ between the two groups. Mean peak VO 2 increased from to ml. kg 1 min 1 following myectomy (P<0 0002) (Fig. 2(a)), and from to ml. kg 1 min 1 (P<0 05) following septal ablation (Fig. 2(b)). The improvement in peak VO 2 was significantly greater following myectomy compared with septal ablation (P=0 02). Similarly, on analysing the percentage predicted peak VO 2 values, a superior benefit was demonstrated with myectomy compared to septal ablation (peak VO 2 increase of 25 12% vs 11 25%, P=0 04). Following myectomy, work rate increased from watts at baseline to watts at follow-up (P=0 04). This compared with a rise in work rate from to watts (P=0 11) following septal ablation. The improvement observed with myectomy was superior to that with septal ablation (P=0 01). Peak oxygen consumption fell in two patients following septal ablation and in one patient following myectomy. The patient in the surgical myectomy group had a drop in systolic fractional shortening from 46% to 31% with a rise in left ventricular end-systolic diameter from 19 mm to 24 mm. The left ventricular end-diastolic diameter was unchanged. Similarly, one of the two patients in the septal ablation group also had a fall in systolic fractional shortening from 50% to 32% with a rise in left ventricular end-systolic diameter from 19 mm to 32 mm and a rise in left ventricular end-diastolic diameter from 38 mm to 47 mm. The remaining patient had no change in echocardiographic dimensions. Twelve month analysis Owing to the different lengths of follow-up between the two groups, a retrospective analysis at 12 months follow-up was carried out. At 12 months follow-up, peak LVOT gradient fell from to mmhg following myectomy (P= ) and from to mmhg (P= ) following septal ablation (P=0 37 for the comparison between the groups). Peak LVOT gradient at 12 months and maximal follow-up were similar with myectomy (17 12 vs mmhg; P=0 32) and with septal ablation (21 12 vs mmhg; P=0 29). The increase in peak VO 2 at 12 months following myectomy was from to ml. kg 1 min 1 (P=0 03) while following septal ablation, the increase was from to ml. kg 1 min 1 (P=0 18). The improvement was significantly greater with myectomy (P=0 04) and similar to the

6 1622 S. Firoozi et al. Figure 2 (a) Change in peak oxygen uptake following myectomy. This graph demonstrates the improvement in peak oxygen consumption following surgical myectomy in each individual patient (solid symbols indicate mean values). (b) Change in peak oxygen uptake following septal ablation. This graph demonstrates the improvement in peak oxygen consumption following alcohol septal ablation in each individual patient (solid symbols indicate mean values). findings at maximal follow-up. The peak VO 2 achieved at 12 months is similar to maximal follow-up in the myectomy ( vs ml. kg 1 min 1 ; P=0 42) and septal ablation groups ( vs ml. kg 1 min 1 ; P=0 81). The increase in work rate at 12 months following myectomy was from to watts (P=0 04) whereas the increase with septal ablation was from to watts (P=0 19). The improvement was significantly greater with myectomy (P=0 03) and similar to the findings at maximal follow-up. The work rate at 12 months was similar to maximal follow-up with myectomy ( vs watts; P=0 38) and septal ablation ( vs watts; P=0 79). Discussion This study demonstrates that, in patients with drug refractory symptomatic obstructive HCM, surgical myectomy and transcoronary alcohol septal ablation are equally effective at reducing left ventricular outflow tract obstruction and lead to similar subjective improvements in functional capacity. Surgical myectomy, however, was

7 Septal myotomy 1623 more effective in improving peak exercise parameters. Although both interventions are acceptable therapies in appropriately selected patients, these data suggest that surgery remains the gold standard against which other therapies should be judged. Recently, two studies have compared the effect of surgical myectomy and alcohol septal ablation on exercise capacity. Nagueh et al. [12] compared subjective and objective outcomes over a 1-year follow-upperiod and showed similar haemodynamic and functional outcomes in both treatment groups. However, different exercise test protocols were used in each cohort and peak oxygen consumption was only indirectly estimated in patients undergoing alcohol septal ablation. In the second study, Qin et al. reported a short term (3 month) follow-up of surgical myectomy and alcohol septal ablation focusing on improvements in NYHA class [13]. Surgery was more effective in reducing outflow tract obstruction and the change in NYHA class in the two cohorts was similar. There was no obvious explanation for the similar improvement in exercise capacity in the face of different degrees of gradient reduction. Effect of gradient reduction on symptoms and exercise capacity The experience with permanent dual chamber pacing in HCM emphasises the importance of peak VO 2 in the assessment of functional capacity. Although studies have reported improvements with active pacing in symptoms and NYHA class, objective assessments of exercise capacity have failed to support these findings [14,15]. Although surgical myotomy myectomy and alcohol ablation resulted in similar improvements in breathlessness and chest pain, subjective reporting of symptoms provides only a semi-quantitative assessment of an individual s exercise capacity and can be substantially influenced by the placebo effect. The measurement of oxygen consumption is a more objective and reliable indicator of true functional capacity and provides specific data on cardiopulmonary performance [16]. In this study, peak VO 2 increased in both treatment groups following outflow tract gradient reduction, but the surgical myectomy group showed greater improvement in peak VO 2 and work rate in comparison to that seen following alcohol septal ablation. Analysis of objective exercise end-points in the two groups in an interim analysis at 1-year following intervention, were consistent with those at the end of the study, indicating that the greater benefit observed in the surgical myectomy group was not due to the longer follow-up period or an associated training effect on exercise testing. Another explanation for the difference in exercise performance may be that myotomy myectomy specifically targets that part of the interventricular septum that makes contact with the anterior mitral valve, whereas septal ablation produces a more diffuse, patchy myocardial scar in the basal septum. However, the precision with which alcohol can be delivered into the septum has been substantially improved with the use of echocardiographic contrast agents prior to injection of alcohol, and in the best hands septal ablation can produce a scar that echocardiographically closely resembles the trough left by surgical myectomy. One obvious functional difference between the techniques is that surgical myectomy typically leads to left bundle branch block (LBBB) [4 10] whereas alcohol septal ablation typically produces a right bundle branch block pattern [17]. The paradoxical septal motion produced by LBBB has been suggested as a mechanism by which dual chamber pacing reduces left ventricular outflow tract obstruction, and it is conceivable that the presence of LBBB following myectomy, but not alcohol septal ablation, conveys some haemodynamic advantage [18,19]. Although the mean reduction in outflow tract gradient was similar in both treatment groups, the proportion of individuals achieving total abolition (gradient <20 mmhg) of the outflow tract gradient was greater following surgical myectomy. It is possible that in some individuals, this resulted in a greater propensity to exercise induced increases in the outflow gradient that in turn resulted in a diminution of peak exercise capacity. Effect on left ventricular function Although left ventricular end-diastolic diameter in both groups remained unaltered, a fall in fractional shortening caused by a small but statistically significant rise in left ventricular end-systolic diameter was observed following surgery and septal ablation. As shortening fraction was derived from M-mode measurements in this study, this probably reflected the reduction in basal septal thickness in most patients [20]. Nevertheless, of the three individuals who experienced deterioration in peak VO 2, two (one surgical and one septal ablation) experienced an 11% decrease in systolic fractional shortening, which may have reflected a deleterious degree of myocardial damage. As expected, left ventricular wall thickness fell in the anterior septal segments in both groups. There was, however, no significant change in the lateral and posterior segments of the left ventricular wall. Mazur et al.[21] have recently reported marked reductions in left ventricular mass and left ventricular wall thickness in all myocardial segments in 26 patients undergoing alcohol septal ablation. Although this more extensive thinning may represent a form of reverse remodelling, the reduction in left ventricular mass correlated strongly with the level of post-procedure creatine kinase and the infarct size on SPECT myocardial scintigraphy. This suggests that the regression of hypertrophy may have been caused by infarction of areas outside the target area of the basal septum. More extensive myocardial infarction may also explain the high incidence of complete heart block (27%) observed in the same study and the long-term consequences of this will only become clearer with longer follow-up.

8 1624 S. Firoozi et al. Study limitations This study was not designed as a prospective investigation, but rather as a retrospective analysis of the two treatment modalities. Patients were assigned to the two treatment modalities based on patient choice and physician guidance and so the two groups may not be comparable. However, with the exception of age the two groups were well matched for baseline clinical, echocardiographic and exercise parameters. As alcohol septal ablations were only performed from 1997 onwards, the follow-up period for myectomy was longer allowing for more cardiac (e.g. remodelling) and peripheral adaptations (e.g. altered endothelial function) to take place. However, an interim analysis at 12 months follow-up revealed similar findings to the long-term follow-up. It has not been our practice to routinely perform provocation of outflow gradients during echocardiographic assessment. We cannot be sure therefore, whether the differences in peak exercise capacity reflect differences in provocable obstruction. Clinical implications and conclusions Myotomy myectomy and alcohol septal ablation appear to be equally effective at improving symptoms in patients with obstructive hypertrophic cardiomyopathy. A prospective registry and large-scale prospective studies are required to determine whether the superior effect of surgery on peak oxygen consumption translates into an important clinical benefit for patients and helps clarify the respective roles of these procedures in the management of obstructive HCM. The authors S.F., M.S.H., B.S. and R.T. were supported by grants from the British Heart Foundation. References [1] Henry WL, Clark CE, Griffith JM, Epstein SE. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am J Cardiol 1975; 35: [2] Ciro E, Nichols PF III, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Two-dimensional echocardiographic analysis. Circulation 1983; 67: [3] Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316: [4] McCully RB, Nishimura RA, Tajik AJ, Schaff V, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996; 94: [5] Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 1978; 57: [6] Koch JP, Maron BJ, Epstein SE, Morrow AG. Results of operation for obstructive hypertrophic cardiomyopathy in the elderly. Septal myotomy and myectomy in 20 patients 65 years of age or older. Am J Cardiol 1980; 46: [7] Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy 2long-term results after surgical therapy. Thorac Cardiovasc Surg 1999; 47: [8] Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987; 76 (5 Pt 2): V [9] Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995; 92 (9 Suppl): II [10] Morrow AG, Reitz BA, Epstein SE et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52: [11] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: [12] Nagueh SF, Ommen SR, Lakkis NM et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: [13] Qin JX, Shiota T, Lever HM et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38: [14] Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998; 31: [15] Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997; 29: [16] Sharma S, Elliott P, Whyte G et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000; 86: [17] Knight C, Kurbaan AS, Seggewiss H et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997; 95: [18] Kappenberger L, Linde C, Daubert C et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J 1997; 18: [19] Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dualchamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: [20] Borer JS, Bacharach SL, Green MV et al. Effect of septal myotomy and myectomy on left ventricular systolic function at rest and during exercise in patients with IHSS. Circulation 1979; 60 (2 Pt 2): [21] Mazur W, Nagueh SF, Lakkis NM et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 20;103:

Medical Policy and and and and

Medical Policy and and and and ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 93799, Unlisted cardiovascular service or procedure Medical Policy Title: Percutaneous Transluminal Septal Myocardial

More information

ORIGINAL PAPER. R. C. Steggerda & J. C. Balt & K. Damman & M. P. van den Berg & J. M. ten Berg

ORIGINAL PAPER. R. C. Steggerda & J. C. Balt & K. Damman & M. P. van den Berg & J. M. ten Berg Neth Heart J (2013) 21:504 509 DOI 10.1007/s12471-013-0453-4 ORIGINAL PAPER Predictors of outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Special interest

More information

Case Presentation: A 58-yearold

Case Presentation: A 58-yearold CLINICIAN UPDATE Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Carey D. Kimmelstiel, MD; Barry J. Maron, MD Case Presentation: A 58-yearold diabetic man was referred for

More information

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Alcohol Septal Ablation (ASA) Nonsurgical technique for septal myocardial reduction Dramatic hemodynamic improvement Technically easy

More information

Patients with hypertrophic cardiomyopathy (HCM) and an

Patients with hypertrophic cardiomyopathy (HCM) and an Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions

More information

Hypertrophic Obstructive Cardiomyopathy

Hypertrophic Obstructive Cardiomyopathy The new england journal of medicine clinical practice Hypertrophic Obstructive Cardiomyopathy Rick A. Nishimura, M.D., and David R. Holmes, Jr., M.D. This Journal feature begins with a case vignette highlighting

More information

marked increase in thickness of walls of heart in patient with HCM.

marked increase in thickness of walls of heart in patient with HCM. Surgical Management of Hypertrophic Obstructive Cardiomyopathy Hani K. Najm MD, Msc, FRCSC, FRCS (Glasg Glasg), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi

More information

The Management of HOCM: What are the Surgical Options

The Management of HOCM: What are the Surgical Options The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College

More information

P atients with hypertrophic cardiomyopathy and an outflow

P atients with hypertrophic cardiomyopathy and an outflow 638 CARDIOVASCULAR MEDICINE Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients F H Gietzen,

More information

*The first two authors contributed equally to this work

*The first two authors contributed equally to this work Original Research Hellenic J Cardiol 2014; 55: 132-138 Surgical Septal Myectomy for Hypertrophic Cardiomyopathy in Greece: A Single-Center Initial Experience Georgios K. Efthimiadis 1*, Antonis Pitsis

More information

Variability of Left Ventricular Outflow Tract Gradient During Cardiac Catheterization in Patients With Hypertrophic Cardiomyopathy

Variability of Left Ventricular Outflow Tract Gradient During Cardiac Catheterization in Patients With Hypertrophic Cardiomyopathy JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.02.014 Variability

More information

HOCM: Alcohol ablation or LVOT Surgery: When and what?

HOCM: Alcohol ablation or LVOT Surgery: When and what? HOCM: Alcohol ablation or LVOT Surgery: When and what? Paul R Vogt/ Pascal A. Berdat Cardiovascular Center Zurich Clinic Im Park Zurich SKG/SGHC Annual Meeting, Zurich, 10.-12.6.15 ASA/Myectomy: Common

More information

Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report

Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report Case Report Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report Junichiro Takahashi, MD, 1 Yutaka Wakamatsu, MD, 1 Jun Okude,

More information

Interventional Imaging Cases

Interventional Imaging Cases Interventional Imaging Cases Steven A. Goldstein MD Professor of Medicine Georgetown University Medical Center MedStar Heart Institute Washington Hospital Center Tuesday, October 10, 2017 DISCLOSURE I

More information

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125 145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency

More information

L Faber, A Meissner, P Ziemssen, H Seggewiss

L Faber, A Meissner, P Ziemssen, H Seggewiss 326 Heart 2000;83:326 331 Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients L Faber, A Meissner, P

More information

The 2014 Mayo Approach to the Management of HCM and Non-Compaction

The 2014 Mayo Approach to the Management of HCM and Non-Compaction The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1 Let

More information

Long-Term Follow-up Impact of Dual-Chamber Pacing on Patients with Hypertrophic Obstructive Cardiomyopathy

Long-Term Follow-up Impact of Dual-Chamber Pacing on Patients with Hypertrophic Obstructive Cardiomyopathy Long-Term Follow-up Impact of Dual-Chamber Pacing on Patients with Hypertrophic Obstructive Cardiomyopathy HU YUE-CHENG, M.D., PH.D.,*, LI ZUO-CHENG, B.S.,*, LI XI-MING, PH.D., M.D.,* DAVID ZHE YUAN, M.D.,*,

More information

A lthough few studies have examined the clinical implications

A lthough few studies have examined the clinical implications 752 CARDIOVASCULAR MEDICINE Pregnancy related complications in women with hypertrophic cardiomyopathy R Thaman, A Varnava, M S Hamid, S Firoozi, B Sachdev, M Condon, J R Gimeno, R Murphy, P M Elliott,

More information

Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy

Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 5, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.07.004 Effect of

More information

Treatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD

Treatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)

More information

Cardiac hypertrophy and how it may break an athlete s heart e the Cypriot case

Cardiac hypertrophy and how it may break an athlete s heart e the Cypriot case Eur J Echocardiography (2005) 6, 301e307 Cardiac hypertrophy and how it may break an athlete s heart e the Cypriot case C.E. Chee a,1, C.P. Anastassiades a,1, A.G. Antonopoulos b, A.A. Petsas b, L.C. Anastassiades

More information

Journal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20.

Journal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20. Journal of the American College of Cardiology Vol. 34, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00341-1 Changes

More information

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto Introduction Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy,

More information

HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy

HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure Paolo Spirito, Genoa, Italy Clinical Substrates for Heart Failure Symptoms in HCM Diastolic dysfunction Atrial fibrillation LV outflow obstruction Evolution

More information

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you

More information

Progressive Left Ventricular Remodeling in Patients With Hypertrophic Cardiomyopathy and Severe Left Ventricular Hypertrophy

Progressive Left Ventricular Remodeling in Patients With Hypertrophic Cardiomyopathy and Severe Left Ventricular Hypertrophy Journal of the American College of Cardiology Vol. 44, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.054

More information

Interventional Cardiology

Interventional Cardiology hic Review Interventional Cardiology Septal reduction therapies in hypertrophic cardiomyopathy: comparison of surgical septal myectomy and alcohol septal ablation Abstract Left ventricular outflow tract

More information

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert

Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you

More information

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015 Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant

More information

Inspiratory Right Ventricular Outflow Obstruction in a Patient with Hypertrophic Cardiomyopathy

Inspiratory Right Ventricular Outflow Obstruction in a Patient with Hypertrophic Cardiomyopathy Case Reports Inspiratory Right Ventricular Outflow Obstruction in a Patient with Hypertrophic Cardiomyopathy Kazufumi TSUCHIHASHI, M.D., Akihito TSUCHIDA, M.D., Nobuichi HIKITA, M.D., Shuji YONEKURA, M.D.,

More information

Nancy Goldman Cutler, MD Beaumont Children s Hospital Royal Oak, Mi

Nancy Goldman Cutler, MD Beaumont Children s Hospital Royal Oak, Mi Nancy Goldman Cutler, MD Beaumont Children s Hospital Royal Oak, Mi Identify increased LV wall thickness (WT) Understand increased WT in athletes Understand hypertrophic cardiomyopathy (HCM) Enhance understanding

More information

Hypertrophic Cardiomyopathy Ud Din Shah, MD; DM; FICC; FESC; FACC

Hypertrophic Cardiomyopathy Ud Din Shah, MD; DM; FICC; FESC; FACC 3 Article 1 Physicians Academy January 2018 Hypertrophic Cardiomyopathy Mehraj Ud Din Shah, MD; DM; FICC; FESC; FACC Hypertrophic Cardiomyopathy (HCM) is a genetic disorder which causes clinically unexplained

More information

Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)

Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services

More information

What s new in Hypertrophic Cardiomyopathy?

What s new in Hypertrophic Cardiomyopathy? What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular

More information

Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)?

Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Sarang Mangalmur+, MD Bryn Mawr Hospital, PA NCVH New Jersey 2015 Disclosures No relevant disclosures

More information

Adult Echocardiography Examination Content Outline

Adult Echocardiography Examination Content Outline Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,

More information

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION Jamilah S AlRahimi Assistant Professor, KSU-HS Consultant Noninvasive Cardiology KFCC, MNGHA-WR Introduction LV function assessment in Heart Failure:

More information

Hypertrophic Cardiomyopathy: beyond gradient and wall thickness

Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic

More information

Assessment of Left Ventricular Outflow Gradient

Assessment of Left Ventricular Outflow Gradient JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 6, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.01.026

More information

Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy, and significance of magnetic resonance in its diagnostics

Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy, and significance of magnetic resonance in its diagnostics cor et vasa 55 (2013) e271 e276 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/crvasa Case Report Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy,

More information

Managing Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology

Managing Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation

More information

Hypertrophic Cardiomyopathy: Patient Management in 2018

Hypertrophic Cardiomyopathy: Patient Management in 2018 Hypertrophic Cardiomyopathy: Patient Management in 2018 Mackram F. Eleid, MD Giornate Cardiologeche Torinesi October 26, 2018 2018 MFMER slide-1 Disclosures No relevant financial relationships to disclose

More information

HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE

HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE Lusyun Kumar Yadav * and Jin li Jun Department of Cardiology,

More information

Journal of the American College of Cardiology Vol. 49, No. 3, by the American College of Cardiology Foundation ISSN /07/$32.

Journal of the American College of Cardiology Vol. 49, No. 3, by the American College of Cardiology Foundation ISSN /07/$32. Journal of the American College of Cardiology Vol. 49, No. 3, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.08.055

More information

Coexistence of asymmetric septal hypertrophy and aortic valve disease in adults

Coexistence of asymmetric septal hypertrophy and aortic valve disease in adults Thorax, 1979, 34, 91-95 Coexistence of asymmetric septal hypertrophy and aortic valve disease in adults M V J RAJ, V SRINIVAS, I M GRAHAM, AND D W EVANS From the Regional Cardiac Unit, Papworth Hospital,

More information

Utility of Two-Dimensional and Doppler Echocardiography in Dual-Chamber Pacing for the Cardiomyopathies

Utility of Two-Dimensional and Doppler Echocardiography in Dual-Chamber Pacing for the Cardiomyopathies Arq Bras Cardiol Conferência Nishimura e col Utility of Two-Dimensional and Doppler Echocardiography in Dual-Chamber Pacing for the Cardiomyopathies Rick Nishimura, John Symanski, David Hurrell, A. Jamil

More information

Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy 019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered

More information

Muscular (hypertrophic) subaortic stenosis (hypertrophic obstructive cardiomyopathy): the evidence for true obstruction

Muscular (hypertrophic) subaortic stenosis (hypertrophic obstructive cardiomyopathy): the evidence for true obstruction Postgraduate Medical Journal (1986) 62, 531-536 Muscular (hypertrophic) subaortic stenosis (hypertrophic obstructive cardiomyopathy): the evidence for true obstruction to left ventricular outflow E. Douglas

More information

Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy

Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,

More information

Journal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20.

Journal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20. Journal of the American College of Cardiology Vol. 33, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00673-1 PERSPECTIVE

More information

Little is known about the degree and time course of

Little is known about the degree and time course of Differential Changes in Regional Right Ventricular Function Before and After a Bilateral Lung Transplantation: An Ultrasonic Strain and Strain Rate Study Virginija Dambrauskaite, MD, Lieven Herbots, MD,

More information

Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy

Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy Journal of the American College of Cardiology Vol. 57, No. 5, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.055

More information

Appendix II: ECHOCARDIOGRAPHY ANALYSIS

Appendix II: ECHOCARDIOGRAPHY ANALYSIS Appendix II: ECHOCARDIOGRAPHY ANALYSIS Two-Dimensional (2D) imaging was performed using the Vivid 7 Advantage cardiovascular ultrasound system (GE Medical Systems, Milwaukee) with a frame rate of 400 frames

More information

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Ömer Aktug 1, MD; Guido Dohmen 2, MD; Kathrin Brehmer 1, MD; Verena Deserno 1 ; Ralf Herpertz 1 ; Rüdiger

More information

ESC Guidelines on Hypertrophic Cardiomyopathy

ESC Guidelines on Hypertrophic Cardiomyopathy 2014 version ES Guidelines on Hypertrophic ardiomyopathy Pr Michel KOMAJDA Dept of ardiology HU PTE SALPETRERE University Pierre et Marie urie PARS FRANE European Heart Journal (2014):doi:10.1093/eurheartj/ehu284

More information

Left ventricular outflow tract obstruction: indications and limitations of current therapies

Left ventricular outflow tract obstruction: indications and limitations of current therapies Left ventricular outflow tract obstruction: indications and limitations of current therapies Costas O Mahony Inherited Cardiovascular Diseases Unit, The Heart Hospital, London, UK. None to declare Conflicts

More information

University of Groningen. Alcohol septal ablation Liebregts, Max

University of Groningen. Alcohol septal ablation Liebregts, Max University of Groningen Alcohol septal ablation Liebregts, Max IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document

More information

Prior Authorization Review Panel MCO Policy Submission

Prior Authorization Review Panel MCO Policy Submission Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

More information

Cardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center

Cardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur

More information

Surgical Myectomy for HOCM

Surgical Myectomy for HOCM Surgical Myectomy for HOCM Volkmar Falk Deutsches Herzzentrum Berlin Different Pathology of HOCM Impact on surgical strategy Said SM Expert Rev Cardiovasc Ther 2013 Different Pathology of HOCM Impact on

More information

Echocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016

Echocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016 Echocardiographic Evaluation of the Cardiomyopathies Stephanie Coulter, MD, FACC, FASE April, 2016 Cardiomyopathies (CMP) primary disease intrinsic to cardiac muscle Dilated CMP Hypertrophic CMP Infiltrative

More information

Cardiac MRI: Cardiomyopathy

Cardiac MRI: Cardiomyopathy Cardiac MRI: Cardiomyopathy Laura E. Heyneman, MD I do not have any relevant financial relationships with any commercial interests Cardiac MRI: Cardiomyopathy Laura E. Heyneman, MD Duke University Medical

More information

Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy

Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.047

More information

Systolic Anterior Motion of Mitral Valve Subchordal Apparatus: A Rare Echocardiographic Pattern in Non- Obstructive Hypertrophic Cardiomyopathy

Systolic Anterior Motion of Mitral Valve Subchordal Apparatus: A Rare Echocardiographic Pattern in Non- Obstructive Hypertrophic Cardiomyopathy Case Report Cardiol Res. 2017;8(5):258-264 Systolic Anterior Motion of Mitral Valve Subchordal Apparatus: A Rare Echocardiographic Pattern in Non- Obstructive Hypertrophic Cardiomyopathy Jezreel L. Taquiso

More information

Left atrial function. Aliakbar Arvandi MD

Left atrial function. Aliakbar Arvandi MD In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial

More information

MITRAL STENOSIS. Joanne Cusack

MITRAL STENOSIS. Joanne Cusack MITRAL STENOSIS Joanne Cusack BSE Breakdown Recognition of rheumatic mitral stenosis Qualitative description of valve and sub-valve calcification and fibrosis Measurement of orifice area by planimetry

More information

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up in 25 Patients

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up in 25 Patients 252 CLINICAL STUDIES JACC Vol. 31, No. 2 HYPERTROPHIC CARDIOMYOPATHY Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up

More information

Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Hypertrophic Cardiomyopathy From Genetics to ECHO Alexandra A Frogoudaki Second Cardiology Department ATTIKON University Hospital Athens University Athens, Greece EUROECHO 2010, Copenhagen, 11/12/2010

More information

Idiopathic Hypertrophic Subaortic Stenosis and Mitral Stenosis

Idiopathic Hypertrophic Subaortic Stenosis and Mitral Stenosis CASE REPORTS Idiopathic Hypertrophic Subaortic Stenosis and Mitral Stenosis Martin J. Nathan, M.D., Roman W. DeSanctis, M.D., Mortimer J. Buckley, M.D., Charles A. Sanders, M.D., and W. Gerald Austen,

More information

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,

More information

Cardiac hypertrophy : differentiating disease from athlete

Cardiac hypertrophy : differentiating disease from athlete Cardiac hypertrophy : differentiating disease from athlete Ario Soeryo Kuncoro, MD, Cardiologist Echocardiography Division, National Cardiovascular Centre Harapan Kita-Jakarta Departement of Cardiology

More information

Clinical Course of Hypertrophic Cardiomyopathy With Survival to Advanced Age

Clinical Course of Hypertrophic Cardiomyopathy With Survival to Advanced Age Journal of the American College of Cardiology Vol. 42, No. 5, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00855-6

More information

Cardiac ultrasound protocols

Cardiac ultrasound protocols Cardiac ultrasound protocols IDEXX Telemedicine Consultants Two-dimensional and M-mode imaging planes Right parasternal long axis four chamber Obtained from the right side Displays the relative proportions

More information

Summary. Introduction

Summary. Introduction J Biomed Clin Res Volume 8 Number 2, 2015 Review Review ALCOHOL SEPTAL ABLATION Desislava P. Petrova, Sotir T. Marchev, Boyko D. Kuzmanov Specialized Hospital for Active Treatment in Cardiology, Pleven

More information

December 2018 Tracings

December 2018 Tracings Tracings Tracing 1 Tracing 4 Tracing 1 Answer Tracing 4 Answer Tracing 2 Tracing 5 Tracing 2 Answer Tracing 5 Answer Tracing 3 Tracing 6 Tracing 3 Answer Tracing 6 Answer Questions? Contact Dr. Nelson

More information

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac

More information

Surgery for Congenital Heart Disease. 1 Its heterogeneity is well documented in terms of clinical

Surgery for Congenital Heart Disease. 1 Its heterogeneity is well documented in terms of clinical Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae Kenji Minakata, MD a Joseph A. Dearani, MD a Rick A. Nishimura, MD b Barry J. Maron,

More information

좌심실수축기능평가 Cardiac Function

좌심실수축기능평가 Cardiac Function Basic Echo Review Course 좌심실수축기능평가 Cardiac Function Seonghoon Choi Cardiology Hallym university LV systolic function Systolic function 좌심실수축기능 - 심근의수축으로심실에서혈액을대동맥으로박출하는기능 실제임상에서 LV function 의의미 1Diagnosis

More information

Doppler-echocardiographic findings in a patient with persisting right ventricular sinusoids

Doppler-echocardiographic findings in a patient with persisting right ventricular sinusoids Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 1990 Doppler-echocardiographic findings in a patient with persisting right

More information

Dynamic left ventricular outflow tract (LVOT) obstruction

Dynamic left ventricular outflow tract (LVOT) obstruction Arrhythmia/Electrophysiology Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy Paul Sorajja, MD; Steve R. Ommen, MD; David R. Holmes, Jr, MD; Joseph A. Dearani, MD; Charanjit

More information

Management of HOCM: Non-Surgical Options

Management of HOCM: Non-Surgical Options Management of HOCM: Non-Surgical Options Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director,

More information

Cardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death

Cardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death Cardiac Conditions in Sport & Exercise Dr Anita Green Cardiac Conditions in Sport Sudden Cardiac Death USA - Sudden Cardiac Death (SCD)

More information

ESSENTIAL MESSAGES FROM ESC GUIDELINES

ESSENTIAL MESSAGES FROM ESC GUIDELINES ESSENTIAL MESSAGES FROM ESC GUIDELINES Committee for Practice Guidelines To improve the quality of clinical practice and patient care in Europe HCM GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC

More information

Aortic stenosis (AS) is common with the aging population.

Aortic stenosis (AS) is common with the aging population. New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting

More information

Highlights from EuroEcho 2009 Echo in cardiomyopathies

Highlights from EuroEcho 2009 Echo in cardiomyopathies Highlights from EuroEcho 2009 Echo in cardiomyopathies Bogdan A. Popescu University of Medicine and Pharmacy, Bucharest, Romania ESC Congress 2010 Hypertrophic cardiomyopathy To determine the differences

More information

Mechanisms of False Positive Exercise Electrocardiography: Is False Positive Test Truly False?

Mechanisms of False Positive Exercise Electrocardiography: Is False Positive Test Truly False? Mechanisms of False Positive Exercise Electrocardiography: Is False Positive Test Truly False? Masaki Izumo a, Kengo Suzuki b, Hidekazu Kikuchi b, Seisyo Kou b, Keisuke Kida b, Yu Eguchi b, Nobuyuki Azuma

More information

Hypertrophic Cardiomyopathy: basics and management

Hypertrophic Cardiomyopathy: basics and management Hypertrophic Cardiomyopathy: basics and management Bette Kim, MD Program Director, Cardiomyopathy Program Director, Roosevelt Hospital Echocardiography Lab Assistant Professor of Clinical Medicine Mount

More information

The Case for Surgery in Obstructive Hypertrophic Cardiomyopathy

The Case for Surgery in Obstructive Hypertrophic Cardiomyopathy Journal of the American College of Cardiology Vol. 44, No. 10, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.04.063

More information

Hypertrophic obstructive cardiomyopathyalcoholseptalablationvs.myectomy:a

Hypertrophic obstructive cardiomyopathyalcoholseptalablationvs.myectomy:a European Heart Journal (2009) 30, 1080 1087 doi:10.1093/eurheartj/ehp016 CLINICAL RESEARCH Heart failure/cardiomyopathy Hypertrophic obstructive cardiomyopathyalcoholseptalablationvs.myectomy:a meta-analysis

More information

PART II ECHOCARDIOGRAPHY LABORATORY OPERATIONS ADULT TRANSTHORACIC ECHOCARDIOGRAPHY TESTING

PART II ECHOCARDIOGRAPHY LABORATORY OPERATIONS ADULT TRANSTHORACIC ECHOCARDIOGRAPHY TESTING PART II ECHOCARDIOGRAPHY LABORATORY OPERATIONS ADULT TRANSTHORACIC ECHOCARDIOGRAPHY TESTING STANDARD - Primary Instrumentation 1.1 Cardiac Ultrasound Systems SECTION 1 Instrumentation Ultrasound instruments

More information

Bulging Subaortic Septum: An Important Risk Factor for Systolic Anterior Motion After Mitral Valve Repair

Bulging Subaortic Septum: An Important Risk Factor for Systolic Anterior Motion After Mitral Valve Repair Bulging Subaortic Septum: An Important Risk Factor for Systolic Anterior Motion After Mitral Valve Repair Sameh M. Said, MD, Hartzell V. Schaff, MD, Rakesh M. Suri, MD, DPhil, Kevin L. Greason, MD, Joseph

More information

Congestive Heart Failure or Heart Failure

Congestive Heart Failure or Heart Failure Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?

More information

Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification

Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification 84th Annual Scientific Meeting of the Aerospace Medical Association May 12-16, 2013 Sheraton Chicago Hotel & Towers,

More information

Pearls & Pitfalls in nuclear cardiology

Pearls & Pitfalls in nuclear cardiology Pearls & Pitfalls in nuclear cardiology Maythinee Chantadisai, MD., NM physician Division of Nuclear Medicine, Department of radiology, KCMH Principle of myocardial perfusion imaging (MPI) Radiotracer

More information

Hypertrophic cardiomyopathy in children

Hypertrophic cardiomyopathy in children Perspective Hypertrophic cardiomyopathy in children Arman Arghami 1, Joseph A. Dearani 1, Sameh M. Said 1, Patrick W. O Leary 2, Hartzell V. Schaff 1 1 Department of Cardiovascular Surgery, 2 Division

More information

The Management of Hypertrophic Cardiomyopathy

The Management of Hypertrophic Cardiomyopathy The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent

More information

PROSTHETIC VALVE BOARD REVIEW

PROSTHETIC VALVE BOARD REVIEW PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve

More information

가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY

가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY 가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY PA c IVS (not only pulmonary valve disease) Edwards JE. Pathologic Alteration of the right heart. In: Konstam MA, Isner M, eds.

More information